Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG reports news on a late-stage ophthalmology and neuro-ophthalmology pipeline focused on eye and optic-nerve disorders with unmet medical need. Company updates commonly cover OCS-01 eye drops for diabetic macular edema, Privosegtor for optic neuritis and other optic neuropathies, and Licaminlimab, a topical anti-TNFα candidate being developed for dry eye disease with a genotype-based approach.
Recurring developments include clinical-program updates, FDA and EMA regulatory interactions, scientific meeting presentations, pipeline reviews, financial results, capital-market communications, annual general meeting materials, and notifications of managerial transactions. Oculis is a Swiss biopharmaceutical company with ordinary shares traded on Nasdaq and Nasdaq Iceland under OCS.
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on eye care, has appointed Daniel S. Char as Chief Legal Officer. Mr. Char brings over 35 years of global legal leadership experience in biotech and medical device companies. He will lead Oculis' legal, compliance, and corporate governance functions.
This appointment aligns with Oculis' strategic plan to advance its innovative pipeline, particularly OCS-01, the first topical eye drop in retina. Mr. Char's extensive expertise includes corporate governance, compliance, drug development and commercialization, financing, licensing, and M&A transactions.
Prior to joining Oculis, Mr. Char served as Chief Legal Officer at ImmunoGen and General Counsel at Evelo Biosciences. He has also held senior legal positions at Smith & Nephew, Targanta Therapeutics, and Biogen. Mr. Char holds a Juris Doctor from Harvard Law School and a Bachelor of Arts in Economics from Tufts University.
Oculis Holding AG (Nasdaq: OCS) and EURETINA have announced Dr. Andrea Govetto as the winner of the inaugural Ramin Tadayoni Award. This award, established in memory of Oculis' late Chief Scientific Officer, aims to support outstanding retina research. Dr. Govetto's winning project focuses on developing a computational model of fluid flow and retinal tissue deformation in macular edema.
The award, presented at the EURETINA congress in Barcelona, includes €30,000 for research support and an additional €5,000 for the awardee. It recognizes promising ophthalmologists in retina research, honoring Prof. Tadayoni's legacy. Dr. Govetto, a vitreoretinal surgeon at Oftalmico-Fatebenefratelli Hospital in Milan, was selected from over 50 competitive submissions.
Oculis CEO, Dr. Riad Sherif, expressed pride in supporting the award and advancing retinal disease research. EURETINA President, Dr. Anat Loewenstein, congratulated Dr. Govetto and highlighted the award's significance in furthering Prof. Tadayoni's contributions to the field.
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on eye care, has announced its participation in three major investor conferences in September 2024:
1. Wells Fargo Healthcare Conference (September 4-6, Boston, MA)
2. H.C. Wainwright 26th Annual Global Investment Conference (September 9-11, New York, NY)
3. Baird Global Healthcare Conference (September 10-11, New York, NY)
Key presentations include CEO Riad Sherif at H.C. Wainwright on September 11 at 9:30 am ET, and CFO Sylvia Cheung at Baird on September 10 at 9:05 am ET. The company will be available for one-on-one meetings during these events. Presentation links will be posted on Oculis' website under the Investors & Media section.
Oculis, a Swiss-based pharmaceutical company trading under the symbol OCS, has filed its Q2 Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) with the SEC on Form 6-K. This follows an earlier press release announcing the same. The filings provide detailed financial information and management's perspective on the company's performance for the second quarter of 2024. Investors and analysts can now access these documents to gain deeper insights into Oculis's financial health, operational performance, and strategic direction.
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) reported Q2 2024 financial results and provided company updates. Key highlights include:
1. Positive topline results from Phase 2b RELIEF trial of OCS-02 for Dry Eye Disease
2. Phase 2 ACUITY trial of OCS-05 for acute optic neuritis on track for Q4 2024 readout
3. Pre-NDA meeting with FDA completed for OCS-01 in post-operative inflammation and pain
4. Cash position of $131.2 million as of June 30, 2024, providing runway into 2H 2026
5. Q2 net loss of $23.0 million, compared to $14.3 million in Q2 2023
6. Raised $59 million in an oversubscribed registered direct offering
The company continues to advance its clinical programs, with strong momentum in DIAMOND-1 and DIAMOND-2 trials for DME.
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) reported Q2 2024 financial results and provided a company update. Key highlights include:
1. Positive topline results from Phase 2b RELIEF trial of OCS-02 for Dry Eye Disease
2. Phase 2 ACUITY trial of OCS-05 for acute optic neuritis on track for Q4 2024 readout
3. Pre-NDA meeting completed for OCS-01 in post-operative inflammation and pain, with NDA submission planned for Q1 2025
4. Cash position of $131.2 million as of June 30, 2024, providing runway into 2H 2026
5. Q2 net loss of $23.0 million, primarily due to increased clinical development expenses
6. Continued progress in Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on eye care, has appointed Dr. Sharon Klier as Chief Development Officer. With over 20 years of experience in ophthalmology clinical development, Dr. Klier will oversee Oculis' ophthalmology pipeline. Her expertise spans early and late-stage programs, regulatory submissions, and approvals, particularly in retinal diseases, neuro-ophthalmology, and ocular inflammation.
Prior to joining Oculis, Dr. Klier served as Chief Development Officer, Head of Ophthalmology at UNITY Biotechnology. She has also held roles at Quark, Allergan, ISTA, and Pfizer. Oculis CEO Dr. Riad Sherif expressed confidence that Dr. Klier's expertise will be important in progressing the company's late-stage pipeline and executing its strategic vision.
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical firm focused on eye care, announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.
Riad Sherif, M.D., CEO of Oculis, will join a panel discussion titled 'Derisked Late-stage Candidates for Retinal Disorders' on August 15, 2024, at 11:00 am ET.
Additionally, Dr. Sherif will give a virtual company presentation available on-demand starting August 15, 2024, at 7:00 am ET.
Access to the presentation and panel discussion will be available through the Oculis website under the Events & Presentation page in the Investors & Media section.
Sabre Gold announced the results of its 2024 Annual General Meeting, held on May 29, 2024. Shareholders approved all agenda items and elected new board members, including Robert K. Warner and Arshad M. Khanani. Additionally, Baruch D. Kuppermann and Frank G. Holz were appointed to the Scientific Advisory Board. The company established a CHF 50 million flexible loan facility with BlackRock, providing significant financial flexibility, though no amounts were drawn at signing. The shareholders approved compensation packages for the Board and Executive Committee, including non-performance-related and variable compensations, as well as equity-based incentives. The company reported a loss of CHF 41.4 million for 2023, which will be carried forward. Key amendments to the articles of association were also approved, including the creation of conditional share capital for bonds and employee incentives.
Oculis Holding AG (Nasdaq: OCS) and EURETINA announced the establishment of the Ramin Tadayoni Award in memory of the late Chief Scientific Officer, Professor Ramin Tadayoni. The award, supported by Oculis, aims to recognize promising ophthalmologists in retina research. It includes €30,000 for research support and an additional €5,000 for the recipient. Applications will be accepted in June and July 2024, with the first award presented at the EURETINA Congress in September. This annual award honors Prof. Tadayoni's legacy and his significant contributions to ophthalmology.